VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | SY-1425 plus azacitidine in RARA-positive newly-diagnosed AML

Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, presents the results of a trial (NCT02807558) investigating the combined treatment of the selective RARa agonist SY-1425, and azacitidine (aza) in RARA-positive, newly-diagnosed, acute myeloid leukemia (AML) patients. The trial was conducted following the identification of preclinical synergistic activity of combined SY-1425 and aza. It was found that RARA+ patients showed an overall response rate of 67%, with complete remission in 61%. The demonstrated clinical benefit of SY-2425 plus aza in RARA+ AML warrants further research. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Dr Eytan Stein, MD, has done consultancy for Amgen, Agios Pharmaceuticals, Celgene Pharmaceuticals, Abbvie, Seattle Genetics, Syndax, Genentech, Biotheryx, Novartis, Astellas Pharmaceuticals and Daiichi-Sankyo; has participated in a board of directors or advisory committee with Agios Pharmaceuticals, Celgene Pharmaceuticals, Genentech, Syros, PTC Therapeutics, Novartis, Astellas Pharmaceuticals and Daiichi-Sankyo; and has received research funding from Celgene Pharmaceuticals, Syndax, Bayer, Novartis and Daiichi-Sankyo.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter